Triumph Capital Management Rigel Pharmaceuticals Inc Transaction History
Triumph Capital Management
- $361 Million
- Q3 2025
A detailed history of Triumph Capital Management transactions in Rigel Pharmaceuticals Inc stock. As of the latest transaction made, Triumph Capital Management holds 100 shares of RIGL stock, worth $4,203. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$4,203% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RIGL
# of Institutions
9Shares Held
365KCall Options Held
0Put Options Held
0-
Telemetry Investments, L.L.C. New York, NY323KShares$13.6 Million0.76% of portfolio
-
Advisory Services Network, LLC31.7KShares$1.33 Million0.01% of portfolio
-
Bergan Kdv Wealth Management, LLC10KShares$420,3000.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA730Shares$30,6810.0% of portfolio
-
Versant Capital Management, Inc224Shares$9,4140.0% of portfolio
About RIGEL PHARMACEUTICALS INC
- Ticker RIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 172,836,000
- Market Cap $7.26B
- Description
- Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...